Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Coagulation Dysfunction and Infection Evaluated in Patients with AECOPD

By LabMedica International staff writers
Posted on 14 Apr 2021
Chronic obstructive pulmonary disease (COPD) is one of the common chronic airway obstructive diseases, characterized by persistent respiratory symptoms and airflow limitation. More...
In acute exacerbation stage (AECOPD), patients developed respiratory failure often have circulatory and coagulation dysfunction, which was considered the cause of thrombosis events in the patients.

Although the inflammation in the early stage of COPD only involves the trachea and lung, hypoxia and further acute inflammation are systemic. In acute exacerbation stage, patients developed respiratory failure often have circulatory and coagulation dysfunction, which was considered the cause of thrombosis events in the patients. The coagulation abnormality could cause pulmonary embolism, myocardial infarction, cerebral infarction, and other thrombosis events in COPD patients.

Respiratory and Critical Care Medicine Scientists from the Anhui Medical University (Hefei, China) performed a retrospective clinical study to investigate the factors correlated to abnormal coagulation status in COPD from November 2016 to November 2019. A total of 135 AECOPD, 44 stable stage COPD patients, and 135 healthy controls were enrolled in this study. The coagulation parameters, blood gas indexes and blood routine examination results were collected and analyzed.

The scientists reported that white blood count (WBC), neutrophil count, neutrophil percentage (N%), platelet (PLT), prothrombin time (PT), international normalized ratio (INR), fibrinogen (FIB), and activated partial thromboplastin time (APTT) increased, plasma thrombin time (TT) decreased in AECOPD group compared with the control group. In AECOPD group, PT, APTT, and FIB were positively correlated with neutrophils and C‐reaction protein levels. PT was positively correlated with partial pressure of carbon dioxide (PCO2) and negatively with pH. Thrombosis was observed in five acute exacerbation and three stable stage COPD patients. In 38 patients with abnormal blood gas analysis indexes, PT level was negatively correlated with pH, positively correlated with arterial partial pressure of carbon dioxide (PaCO2) levels indicating abnormal coagulation status was correlated to hypercapnia and acidosis.

The authors concluded that their study revealed that coagulation dysfunction existed in AECOPD patients. The abnormal coagulation was correlated to infection and hypercapnia and might be the main cause of thrombosis in the patients. The study was published on March 25, 2021 in the Journal of Clinical Laboratory Analysis.

Related Links:
Anhui Medical University


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
New
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
New
Fully Automated Urinalysis System
DxU 1800 Fully Automated Urinalysis System
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.